The pharmacy industry is under increasing scrutiny from all angles. Whether at the legislative or agency level, Washington as well as many states seem intent on addressing perceived issues surrounding drug pricing, reimbursement, and program integrity. For these reasons, Mintz Levin and ML Strategies brought together stakeholders and thought leaders from across the industry to share knowledge and insight on this rapidly shifting landscape at the 2016 Mintz Levin/ML Strategies Pharmacy Industry Summit in Washington, DC on May 10.
For those of you who were unable to join us, you may download the presentation materials here. Additionally, as drug pricing was a common thread throughout the Summit, those in the pharmacy industry may also be interested in a recent ML Strategies White Paper "Transparency in Drug Pricing:Issues to Consider from the Research Lab to the Consumer."
Here's some of the #MLPharma Twitter buzz:
See you next year in DC!
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
